Tyra Biosciences, Inc. (TYRA): Price and Financial Metrics

Tyra Biosciences, Inc. (TYRA): $7.92

0.25 (+3.26%)

POWR Rating

Component Grades













Add TYRA to Watchlist
Sign Up

Industry: Biotech



in industry

TYRA Stock Price Chart Interactive Chart >

Price chart for TYRA

TYRA Price/Volume Stats

Current price $7.92 52-week high $31.36
Prev. close $7.67 52-week low $6.25
Day low $7.45 Volume 48,700
Day high $8.15 Avg. volume 100,335
50-day MA $9.30 Dividend yield N/A
200-day MA $0.00 Market Cap 330.75M

Tyra Biosciences, Inc. (TYRA) Company Bio

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Latest News Stream

Event/Time News Detail
Loading, please wait...

TYRA Latest Social Stream

Loading social stream, please wait...

View Full TYRA Social Stream

Latest TYRA News From Around the Web

Below are the latest news stories about Tyra Biosciences Inc that investors may wish to consider to help them evaluate TYRA as an investment opportunity.

Tyra Biosciences surges 14% as owner Boxer Capital buys 125,000 shares

No summary available.

Seeking Alpha | December 22, 2021

Tyra Biosciences Inc (NASDAQ:TYRA) Major Shareholder Boxer Capital, Llc Acquires 125,000 Shares

Tyra Biosciences Inc (NASDAQ:TYRA) major shareholder Boxer Capital, Llc acquired 125,000 shares of the businesss stock in a transaction that occurred on Friday, December 17th. The stock was bought at an average cost of $13.12 per share, for a total transaction of $1,640,000.00. The purchase was disclosed in a filing with the Securities & Exchange []

Dakota Financial News | December 22, 2021

Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...

Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc.

Yahoo | December 21, 2021

Head-To-Head Review: Tyra Biosciences (NASDAQ:TYRA) vs. Gain Therapeutics (NASDAQ:GANX)

Tyra Biosciences (NASDAQ:TYRA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings. Insider and Institutional Ownership 51.6% of Tyra Biosciences shares are held by institutional investors. Comparatively, [] The post Head-To-Head Review: Tyra Biosciences (NASDAQ:TYRA) vs. Gain Therapeutics (NASDAQ:GANX) appeared first on ETF Daily News .

ETF Daily News | December 15, 2021

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | December 15, 2021

Read More 'TYRA' Stories Here

TYRA Price Returns

1-mo 11.55%
3-mo -33.94%
6-mo -68.29%
1-year N/A
3-year N/A
5-year N/A
YTD -43.71%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7219 seconds.